159 related articles for article (PubMed ID: 29532734)
1. Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T).
Tanaka Y; Takeuchi T; Harigai M; Yamanaka H; Nakano T; Akagi K; Ukyo Y; Hsu B
Mod Rheumatol; 2019 Mar; 29(2):306-313. PubMed ID: 29532734
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sirukumab in Japanese patients with moderate to severe rheumatoid arthritis inadequately controlled by disease modifying anti-rheumatic drugs: Subgroup analysis of a phase 3 study.
Takeuchi T; Tanaka Y; Yamanaka H; Harigai M; Nakano T; Akagi K; Ukyo Y; Hsu B
Mod Rheumatol; 2018 Nov; 28(6):941-949. PubMed ID: 29336187
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
[TBL] [Abstract][Full Text] [Related]
4. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy.
Smolen JS; Weinblatt ME; Sheng S; Zhuang Y; Hsu B
Ann Rheum Dis; 2014 Sep; 73(9):1616-25. PubMed ID: 24699939
[TBL] [Abstract][Full Text] [Related]
5. Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.
Takeuchi T; Thorne C; Karpouzas G; Sheng S; Xu W; Rao R; Fei K; Hsu B; Tak PP
Ann Rheum Dis; 2017 Dec; 76(12):2001-2008. PubMed ID: 28855173
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study.
Taylor PC; Schiff MH; Wang Q; Jiang Y; Zhuang Y; Kurrasch R; Daga S; Rao R; Tak PP; Hsu B
Ann Rheum Dis; 2018 May; 77(5):658-666. PubMed ID: 29483080
[TBL] [Abstract][Full Text] [Related]
7. Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients.
Takeuchi T; Yamanaka H; Harigai M; Tamamura R; Kato Y; Ukyo Y; Nakano T; Hsu B; Tanaka Y
Arthritis Res Ther; 2018 Mar; 20(1):42. PubMed ID: 29514712
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE).
Aletaha D; Bingham CO; Karpouzas GA; Takeuchi T; Thorne C; Bili A; Agarwal P; Hsu B; Rao R; Brown K; Tanaka Y
RMD Open; 2021 Jan; 7(1):. PubMed ID: 33526709
[TBL] [Abstract][Full Text] [Related]
9. Exposure-Response Modeling Analyses for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin 6, in Patients With Moderately to Severely Active Rheumatoid Arthritis.
Xu Y; Hu C; Zhuang Y; Hsu B; Xu Z; Sharma A; Zhou H
J Clin Pharmacol; 2018 Nov; 58(11):1501-1515. PubMed ID: 29901815
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a Phase IIa study.
Takeuchi T; Tanaka Y; Close D; Godwood A; Wu CY; Saurigny D
Mod Rheumatol; 2015 Jan; 25(1):21-30. PubMed ID: 24720551
[TBL] [Abstract][Full Text] [Related]
11. Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab.
Hu C; Xu Y; Zhuang Y; Hsu B; Sharma A; Xu Z; Zhang L; Zhou H
J Pharmacokinet Pharmacodyn; 2018 Oct; 45(5):679-691. PubMed ID: 29961161
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
13. Investigating sirukumab for rheumatoid arthritis: 2-year results from the phase III SIRROUND-D study.
Thorne C; Takeuchi T; Karpouzas GA; Sheng S; Kurrasch R; Fei K; Hsu B
RMD Open; 2018; 4(2):e000731. PubMed ID: 30564449
[TBL] [Abstract][Full Text] [Related]
14. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
[TBL] [Abstract][Full Text] [Related]
15. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Tabalumab, an Anti-B-Cell-Activating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population: Results From a Randomized, Placebo-Controlled, Phase 3 Trial (FLEX-O).
Genovese MC; Silverman GJ; Emery P; Gupta RC; Gill A; Veenhuizen M; Xie L; Komocsar WJ; Berclaz PY; Lee C
J Clin Rheumatol; 2015 Aug; 21(5):231-8. PubMed ID: 26203826
[TBL] [Abstract][Full Text] [Related]
17. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
Szepietowski JC; Nilganuwong S; Wozniacka A; Kuhn A; Nyberg F; van Vollenhoven RF; Bengtsson AA; Reich A; de Vries DE; van Hartingsveldt B; Robinson DW; Gordon R; Hsu B
Arthritis Rheum; 2013 Oct; 65(10):2661-71. PubMed ID: 23896980
[TBL] [Abstract][Full Text] [Related]
18. Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study.
Blanco FJ; Möricke R; Dokoupilova E; Codding C; Neal J; Andersson M; Rohrer S; Richards H
Arthritis Rheumatol; 2017 Jun; 69(6):1144-1153. PubMed ID: 28217871
[TBL] [Abstract][Full Text] [Related]
19. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
[TBL] [Abstract][Full Text] [Related]
20. Confirmatory Population Pharmacokinetic Analysis for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin-6, in Patients With Moderately to Severely Active Rheumatoid Arthritis.
Xu Y; Hu C; Zhuang Y; Hsu B; Xu Z; Zhou H
J Clin Pharmacol; 2018 Jul; 58(7):939-951. PubMed ID: 29578578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
